Zobrazeno 1 - 10
of 40
pro vyhledávání: '"PAF acetylhydrolase activity"'
Autor:
Tiemann, U. a, *, Tomek, W. a, Schneider, F. a, Wollenhaupt, K. a, Kanitz, W. a, Becker, F. a, Pöhland, R. a, Alm, H. a
Publikováno v:
In Prostaglandins and Other Lipid Mediators 2001 65(2):125-141
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Lipoprotein(a) [Lp( a)] plays an important role in atherosclerosis. The biological effects of Lp( a) have been attributed either to apolipoprotein(a) or to its low-density lipoprotein-like particle. Lp( a) contains platelet-activating factor acetylhy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::87008b306d7530f2ced069dc4b137f37
http://olympias.lib.uoi.gr/jspui/handle/123456789/8575
http://olympias.lib.uoi.gr/jspui/handle/123456789/8575
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD
Autor:
Siamopoulos, K. C., Gouva, C., Katopodis, K. P., Tzallas, C., Nikolopoulos, P., Papavasiliou, E. C., Tselepis, A. D.
Background. Among lipid abnormalities observed in patients with chronic kidney disease (CKD) is a significant decrease in serum high-density lipoprotein cholesterol (HDL-C) levels. In a previously published randomized control trial, we showed that ea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::3a0f8cdae86e547d39d346d900e78fa8
http://olympias.lib.uoi.gr/jspui/handle/123456789/8384
http://olympias.lib.uoi.gr/jspui/handle/123456789/8384
Autor:
Yves Denizot, Véronique Truffinet, Muriel Mathonnet, Cubertafond P, Gainant A, Stephane Bouvier
Publikováno v:
Mediators of Inflammation
Mediators of Inflammation, Hindawi Publishing Corporation, 2004, 13 (1), pp.53-4. ⟨10.1080/09629350410001664824⟩
Mediators of Inflammation, Vol 13, Iss 1, Pp 53-54 (2004)
Mediators of Inflammation, Hindawi Publishing Corporation, 2004, 13 (1), pp.53-4. ⟨10.1080/09629350410001664824⟩
Mediators of Inflammation, Vol 13, Iss 1, Pp 53-54 (2004)
This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.
Autor:
S.-A. Karabina, A.D. Tselepis, C. Tziallas, M.P. Vini, H. J. Milionis, H. Bairaktari, M.S. Elisaf, K.C. Siamopoulos
Atherosclerosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::064d8d90e015ef80edbe26b1505d9f69
http://olympias.lib.uoi.gr/jspui/handle/123456789/20863
http://olympias.lib.uoi.gr/jspui/handle/123456789/20863
Publikováno v:
Shock (Augusta, Ga.). 7(3)
Our basic laboratory work has identified the postischemic gut as a source of platelet-activating factor (PAF), which primes circulating neutrophils for the production of reactive oxygen metabolites (ROMs) leading to distant organ injury. Circulating
Publikováno v:
Life sciences. 59(10)
PAF-AH activity was determined in pancreas homogenates. The enzyme activity was moderately stable upon storage at −20 °C. PAF and lyso-PAF were identified in rat pancreas and their concentrations were determined. PAF levels and PAF-AH activity wer
Publikováno v:
Atherosclerosis Supplements. 4:287-288